New Portfolio of Surfaces for Cell-Based Drug Discovery Screening and Basic Cell Culture Research
“Today’s life scieonce researchers are increasingly using primary cells, transfected cells and stem cells in research and drug discovery assays. These fastidious cells often require optimised cell culture surfaces to achieve reproducible and consistent assay results,” said Carolyn James, Country Business Leader UK and Ireland, BD Biosciences. “BD Biosciences is committed to providing researchers with advanced surfaces that enable them to utilise these cells in a highly defined and controlled cell culture environment.”
In basic cell culture research, scientists are looking for methods to improve cell growth and reduce or remove the serum in culture media to save costs and reduce variability. BD PureCoat surfaces improve cell attachment, increase proliferation and enhance recovery from freeze-thaw for a variety of primary, transfected and transformed cells in serum-reduced or serum-free culture conditions. This allows researchers to produce more cells in better-defined conditions.
In cell-based drug discovery screening, scientists often culture transfected and cryopreserved division-arrested cells for use in cell-based screening assays. Strong attachment of these cells is critical to achieving a robust assay, and cell monolayer consistency is directly related to reproducible assay results. BD PureCoat surfaces maintain the integrity of the cell monolayer, offering superior consistency in cell-based assays versus standard tissue-culture surfaces.
The new BD PureCoat amine and carboxyl surfaces utilize a proprietary thin-film coating technology to produce a uniform, functionalised surface for cell culture.